Related coverage linked through entity extraction aliases.
Aug 12, 2026
At ESMO GI 2026, experts presented the EBAI framework classifying AI-based biomarkers into three validation tiers. Clinical data showed AI detecting MSI with 96-98% sensitivity and MRI-guided brachytherapy improving recurrence-free survival.
Aug 11, 2026
First Ascent Biomedical opened a CLIA- and CAP-certified FPM lab in Miami, testing FDA-approved drugs on patient tumor cells with results in ~10 days. Sponsored testing is available for eligible Florida residents and colorectal cancer patients.
Jul 27, 2026
At ESMO GI 2026, the GALAXY study showed ctDNA tests can identify colorectal cancer patients who benefit from adjuvant chemotherapy. A separate study found CLK3 regulates colorectal tumor angiogenesis by stabilizing HIF1α.
Aug 02, 2026
A major clinical trial found that Grail's Galleri blood test did not reduce late-stage cancer diagnoses, raising questions about multi-cancer early detection. Meanwhile, the FDA approved a second blood-based colorectal cancer screening test, and an AI-powered liquid biopsy showed promise for Ewing sarcoma.
Jul 28, 2026
AI identified rectal cancer patients who benefit from adding irinotecan to chemoradiotherapy, cutting recurrence and death risk. Separate research finds most online AI-cancer information is low quality and too complex for patients.
Jul 10, 2026
Screening with colonoscopy or FIT in 278,280 Swedish 60-year-olds detected more stage I-II colorectal cancers than usual care, with advanced cases declining. Adverse gastrointestinal and cardiovascular events rose slightly in the first year.
Jul 29, 2026
Colorectal Cancer Alliance tackles rising young-onset cases with Never Too Young Taskforce and Project Cure CRC; LEAD FROM BEHIND wins Webby Award. Screening changes make 20M more eligible.
Jul 19, 2026
Amgen detailed its T-cell engager and precision therapy strategy at Citi's 2026 summit. GT Biopharma, Onco-Innovations, Oncotelic, and Samsung Biologics also advanced AI and organoid platforms in drug development.
May 29, 2026
At ASCO 2026, Rutgers and Ohio State researchers present new breast cancer combination data, lymphoma survival analyses, and a drug donation program that cut medication wait times to about six days.
May 05, 2026
TuHURA Biosciences filed an FDA IND for TBS-2025, a VISTA-targeting antibody, plus a menin inhibitor in mutNPM1 r/r AML. Phase 2 targets early Q2 2026 with preliminary Stage 1 results in Q3 2026.
Apr 29, 2026
New studies present SPARK, an AI framework for tumor analysis, a Cell review of liver cancer hallmarks and treatments, and a call for more research into lung cancer in never-smokers, which was the fifth most common cause of cancer death in 2020.
Aug 05, 2026
Two studies link delayed colorectal cancer treatment to worse outcomes. A JAMA Oncology study of 112,672 patients found delays over six weeks hurt survival. High socioecological burden also delays care.
Jun 15, 2026
Most advanced cancer patients misunderstand whether their treatment is curative. Honest prognosis discussions improve outcomes without worsening distress, while diagnostic delays persist; pathologist involvement can speed treatment.
Jun 28, 2026
FDA granted early access to a pancreatic cancer drug; final ARROW data for pralsetinib in RET+ NSCLC were published. A Sarah Cannon Research Institute official outlined a tissue-agnostic vision and highlighted new oncology research.
Aug 07, 2026
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Jul 24, 2026
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Jul 31, 2026
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Jun 02, 2026
AI-driven studies are advancing cancer drug discovery across multiple tumor types, including a pan-cancer proposal of AMG-900, a novel gp130 inhibitor for colorectal cancer, and the Kinic Index for hepatocellular carcinoma. Machine learning is also being integrated into computational platforms like Isomorphic Labs' IsoDDE to model molecular interactions.
Mar 21, 2026
Incyte executives presented a post-Jakafi growth strategy at the Barclays conference, outlining four product launches and pipeline progress in hematology, immunology, and solid tumors ahead of Jakafi's loss of exclusivity in 2029.
Jul 28, 2026
A study finds end-to-side anastomosis for Crohn’s disease may reduce endoscopic recurrence, while global data show early-onset colorectal cancer has the highest GI cancer burden in young adults, with rising incidence. Both studies highlight evolving challenges and treatment options in gastroenterology.
